Survodutide dosing & administration
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Titration schedule
0.6 mg
Frequency
Once weekly
Duration
Initiation, part of a 20-week up-titration
Phase 2 starting dose; gradual escalation reduces GI side effects [1].
3.6 mg
Frequency
Once weekly
Duration
26-week maintenance after escalation
Maintenance dose in the phase 2 dose-finding trial; ~12.5% mean weight loss [1].
4.8 mg
Frequency
Once weekly
Duration
26-week maintenance after escalation
Highest dose studied; up to ~14.9% mean weight loss over 46 weeks [1].
Timing
Best time to take
Administer Survodutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Survodutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Survodutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Survodutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Survodutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Survodutide. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Nausea, Vomiting, Diarrhea, Decreased Appetite
Less common: Constipation and Abdominal Pain
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Survodutide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Survodutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Other GLP-1 Receptor Agonists — Redundant GLP-1R activation with no additional benefit and increased gastrointestinal adverse events
- Insulin Secretagogues — Increased hypoglycemia risk when combined with agents that stimulate insulin secretion independent of glucose levels
- Glucagon for Hypoglycemia Rescue — Survodutide's glucagon receptor agonism may alter the pharmacodynamics of exogenous glucagon used in hypoglycemia emergencies
Published research
What the studies show
le Roux CW, Steen O, Lucas KJ, et al. · 2024
Survodutide, a dual glucagon/GLP-1 agonist, dose-dependently reduced body weight by 6-15% with maximum effects at higher doses in 46-week Phase 2 obesity trials.
Blüher M, Rosenstock J, Hoefler J, et al. · 2024
Research (2024) on survodutide contributes important scientific knowledge about its biological and pharmacological properties.
Zimmerman T, et al. · 2022
Research (2022) demonstrates survodutide's efficacy in clinical treatment and therapeutic applications.
Kosiborod MN, Platz E, Wharton S, et al. · 2024
Clinical evidence (2024) supports the therapeutic use of survodutide in medical treatment protocols.
Thomas L, Martel E, Rist W, et al. · 2024
Clinical trial (2024) provides evidence for survodutide's effectiveness in therapeutic management.
Head to head
Survodutide compared
Want the full picture?
The complete Survodutide research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.